20 October 2025
20 October 2025
The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD¡¯s dominance in the PD-1 space.
These Phase III results could enhance Verzenio¡¯s uptake alongside ET in the adjuvant breast cancer setting, if approved.
The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.
The new scheme slashes FDA review times to 1-2 months for eligible drug candidates.
The availability of a rule-in-rule-out test for Alzheimer¡¯s disease in primary care settings is likely to drive efficiencies throughout the care continuum.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
